Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

This study was sponsored by Eli Lilly and Company. Sims and 15 co-authors were employees of and shareholders in Eli Lilly during the conduct of the study. Other co-authors reported relationships ...

Eli Lilly has launched ... but it also covers diabetes and migraine drugs, respectively, via telehealth providers 9amHealth and Cove. According to the company, it allows “consistent access ...

Eli Lilly's drive to provide ... programmes do not systematically cover people living with obesity for medical care — this needs to change," said Lilly's head of cardiometabolic health, Patrik ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...